Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01242371 · ClinicalTrials.gov registry record · NA
Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia
A NA study of Schizophrenia and Schizoaffective Disorder, sponsored by Sheppard Pratt Health System.
- Completed
- Registry status
- NA
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT01242371: Completed NA study of Schizophrenia and Schizoaffective Disorder, sponsored by Sheppard Pratt Health System.
NCT01242371 is a NA study of Schizophrenia and Schizoaffective Disorder that has completed, run by Sheppard Pratt Health System. The registered enrollment target is 65 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01242371, a NA study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by Sheppard Pratt Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the administration of a probiotic supplement when used in addition to standard antipsychotic medications.
Primary Outcome
The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Probiotic Supplement
- DIETARY_SUPPLEMENT Identical-appearing Placebo
Study Locations (1)
Maryland
- Sheppart Pratt Health System - Towson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-08 |
| Phase | NA |
What the finished NCT01242371 record still lists
NCT01242371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Probiotic Supplement is the first listed.
NCT01242371 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01242371 about?
NCT01242371 is a clinical study titled "Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia". The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the administration of a probiotic supplement when used in addition to standard antipsychotic medications.
What is the current status of trial NCT01242371?
This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2010-08. Estimated completion is 2012-08.
What conditions does trial NCT01242371 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT01242371?
The interventions under investigation include: Probiotic Supplement (DIETARY_SUPPLEMENT), Identical-appearing Placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01242371?
This trial is sponsored by Sheppard Pratt Health System, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01242371 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01242371's enrollment target sits among peer trials
65 184th of 315 higher than 132 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia